Cramer's 'Mad Money' Recap: Look to Housing and Insurance

Tickers in this article: AIG ANR BIIB EXC GLD HD IVR LL LOW NLY OC PFE PIR QCOR REGN SHW TRV VMC WHR WY

Pfizer's weekly chart also was bullish, noted Collins, with the stock trading sideways during the first half of 2012, only to enter a bullish channel during the back half of 2012. Currently the stock is consolidating again and Collins thinks the uptrend is not far away.

Cramer said he's already on record as saying Pfizer could repeat its 15% gain from last year. He said that's big news for a sleepy stock like Pfizer that lets invests sleep enough and offers a big dividend yield to boot.

Lightning Round

In the Lightning Round, Cramer was bullish on Lumber Liquidators (LL) , Home Depot (HD) , Alpha Natural Resources (ANR) , Invesco Mortgage Capital (IVR) and Annaly Capital (NLY) .

Cramer was bearish on Exelon (EXC) , Lowe's (LOW) and Questcor Pharmaceuticals (QCOR) .

Healthy Biogen

In his second "Executive Decision" segment, Cramer spoke with Dr. George Scangos, CEO of Biogen Idec (BIIB) , another biotech company presenting this week at JPMorgan's annual health-care conference.

Scangos started off by updating investors on his company's treatments for muscular sclerosis. He said Biogen's two current injectable treatments are doing very well and his company expects approval of BG12, a new oral medication for the disease, possibly as early as March of this year.

When asked whether the new pill could cannibalize the injectable treatments, Scangos said many patients are happy with their current treatments and have their disease under control, so there will be little incentive to switch.

Scangos continued that all three of Biogen's MS drugs treat different segments of the population and he's delighted to have three options for patients. He was also upbeat about his company's two new hemophilia drugs, which will allow patients to inject themselves less frequently. He said those drugs will provide a great service to patients.

Finally, when asked about the disappointing results for Biogen's ALS drug, results that forced the company to stop development, Scangos said Biogen has had three clinical trial successes and one failure last year. While it's very disappointing to see a drug fail, the company remains committed to doing more work and returning to trials with a new drug for ALS.

Cramer said Biogen is another great biotech firm worthy of continued investment.

No Huddle Offense

In his "No Huddle Offense" segment, Cramer stood up in defense of gold, a commodity he said is finally providing the long-awaited pullback that everyone has been expecting.

Cramer said there are dozens of so-called reasons to not like gold, but the precious metal has delivered gain after gain.

Yes, gold has been stalled of late, but with so many countries printing money and sending their currencies lower, it's only a matter of time before gold marches higher.

He said the simple economics of gold say it's getting harder, and more costly, to find gold, which can only mean good things for the SPDR Gold Shares (GLD) going forward.